ArticleInternational ophthalmology2025
Quality of life in patients with progressive keratoconus treated with corneal collagen crosslinking.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Evaluation of Factors Influencing Quality of Life in Keratoconus Patients Using the Keratoconus Outcomes Research Questionnaire (KORQ).Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Article
- Vision-Related Quality of Life in Iraqi Keratoconus Patients: A Comparative Analysis of Surgical and Nonsurgical Interventions.Korean journal of ophthalmology : KJO · 2026Article
- The Future of Interventional Keratoconus Management: Perspectives on Integrating Epithelium-on Oxygen-Enriched Cross-Linking into Comprehensive Care Pathways.Therapeutics and clinical risk management · 2026Article
- Evaluation of corneal stromal demarcation line depth after corneal collagen cross-linking with two different UV energy levels in keratoconus: a comparative study using AS-OCT andInternational journal of ophthalmology · 2026Article
- Interventional Keratoconus Management: The Critical Imperative for Early Detection and Treatment.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to analyze the vision-related quality of life (vr-QoL) in keratoconus (KC) patients after corneal crosslinking (CXL).
methodsA prospective clinical study was conducted, wherein 41 patients underwent assessment using the "National Eye Institute Visual Functioning Questionnaire" (NEI-25) and the "Keratoconus Outcomes Research Questionnaire" (KORQ) to evaluate vr-QoL, along with the examination of morphology and functional parameters before CXL, and at three and six months post-treatment. Rasch analyses were used to verify the measurement precision of the KORQ with our study population.
resultsThere were no statistically significant changes observed in corneal morphology and best corrected visual acuity after CXL. Analysis of the NEI-25 questionnaires and KORQ demonstrated no statistically significant changes throughout the follow-up period. Rasch analyses revealed a high measurement precision of the KORQ within our population.
conclusionThe study indicates that patients with progressive KC maintain stable vr-QoL after undergoing CXL. Based on our findings, we suggest considering very early CXL treatment for KC patients that are at high risk of progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.